PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
International Journal of Molecular Sciences · 09.03.2024 · 25 (6) · 3178
DOI: 10.3390/ijms25063178 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.03.2024. Verfasst von Premila D Leiphrakpam und 1 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Medical Education, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Colorectal Neoplasms. Die Arbeit wurde bisher 210-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In the last decade, pathway-specific targeted therapy has revolutionized colorectal cancer (CRC) treatment strategies. This type of therapy targets a tumor-vulnerable spot formed primarily due to an alteration in an oncogene and/or a tumor suppressor gene. However, tumor heterogeneity in CRC frequently results in treatment resistance, underscoring the need to understand the molecular mechanisms involved in CRC for the development of novel targeted therapies. The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of the rapamycin (PI3K/Akt/mTOR) signaling pathway axis is a major pathway altered in CRC. The aberrant activation of this pathway is associated with CRC initiation, progression, and metastasis and is critical for the development of drug resistance in CRC. Several drugs target PI3K/Akt/mTOR in clinical trials, alone or in combination, for the treatment of CRC. This review aims to provide an overview of the role of the PI3K/Akt/mTOR signaling pathway axis in driving CRC, existing PI3K/Akt/mTOR-targeted agents against CRC, their limitations, and future trends.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Medical Education, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Division of Surgical Oncology, Department of Surgery, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
ORCID-Profile: Premila D Leiphrakpam
Zitieren
APA
Leiphrakpam, P. D., & Are, C. (2024). PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment. International Journal of Molecular Sciences, 25(6), 3178. https://doi.org/10.3390/ijms25063178
Vancouver
Leiphrakpam PD, Are C. PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment. International Journal of Molecular Sciences. 2024;25(6):3178. doi:10.3390/ijms25063178
BibTeX
@article{Leiphrakpam2024,
author = {Leiphrakpam, Premila D and Are, Chandrakanth},
title = {PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {6},
pages = {3178},
doi = {10.3390/ijms25063178}
}
EUVIMED